Skip to content
OpenCapital
Get started

AnaptysBio, Inc. ANAB Available For Sale Securities Debt Securities Current

Available For Sale Securities Debt Securities Current at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$912M+0.6%
Pfizer logo
PfizerPFE
——
Biogen logo
BiogenBIIB
——
BridgeBio Pharma logo
BridgeBio PharmaBBIO
——
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
——

Other financials

Income statement

See full
Revenue$25.6M-8.0%
Operating income-$34.6M-25.8%
Net income-$52.9M-34.5%
EPS (diluted)-$1.84-43.8%

Balance sheet

See full
Cash & equivalents$248.5M+152%
Total debt$13.6K-99.9%
Total equity$12.7M-62.5%
Total assets$329.7M-21.9%

Cash flow

See full
Operating cash flow-$25.9M-142%
CapEx$17.0K-51.4%
Free cash flow-$25.9M-142%

Valuation

See full
Market cap$1.73B+180%
Enterprise value$1.48B+176%
P/S7.4×+1.9×

Profitability

See full
Operating margin17.6%+9.6pp
Net margin-49.9%-22.6pp
FCF margin1.9%+1.0pp

Returns & leverage

See full
Return on equity-343.8%-1,012pp
Debt / equity0×-0.5×
Current ratio7.6×-0.7×

Where this comes from

Reported directly by AnaptysBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The official record: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about AnaptysBio, Inc.'s available for sale securities debt securities current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AnaptysBio, Inc.'s available for sale securities debt securities current?
AnaptysBio, Inc. (ANAB) reported available for sale securities debt securities current of $37.99M in Q1 2026.
How has AnaptysBio, Inc.'s available for sale securities debt securities current changed year-over-year?
AnaptysBio, Inc.'s available for sale securities debt securities current decreased by 84.3% year-over-year, from $241.3M to $37.99M.
What is the long-term trend for AnaptysBio, Inc.'s available for sale securities debt securities current?
Over 5 years (2020 to 2025), AnaptysBio, Inc.'s available for sale securities debt securities current has grown at a -12.5% compound annual growth rate (CAGR), from $143.2M to $73.44M.